(via TheNewswire)

Vancouver, British Columbia – TheNewswire - March 18, 2026 – Noveris Health Sciences Inc. (the “ Company ”) (CSE: NVRS) (FSE: 0NF0) (OTC: MYCOF) is pleased to announce that it has completed its previously announced non-brokered private placement and issued  9,625,049 units (each, a “ Unit ”) at a price of $0.24 per Unit for gross proceeds of $2,310,011.76 (the “ Offering ”).

Each Unit consists of: (i) one common share of the Company and (ii) one common share purchase warrant, with each warrant entitling the holder thereof to acquire one additional common share of the Company at an exercise price of $0.30 for a period of 24 from the date of issuance.  

The Units (and underlying securities comprising the Units) were issued pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 – Prospectus Exemptions and will not be subject to statutory hold periods in compliance with Canadian securities laws.

In connection with the Offering, the Company paid an aggregate of $28,050.60 in cash finder’s fees to arm’s length finders.

The proceeds raised from the Offering are intended to be used for general working capital, general and administrative expenses, and research and development.

NOVERIS HEALTH SCIENCES INC.

Jason Birmingham  

Chief Executive Officer  

Tel: +1 778-900-NVRS (6877)  

Investor Relations Email: fair@noveris.health  

Web: http://noveris.health

About Noveris Health Sciences Inc.  

The Company is a biotechnology company developing the next generation of innovative medications and therapies to address mental health disorders such as nicotine addiction and posttraumatic stress disorder (PTSD). The core strategy blends advanced technology with an elaborate infrastructure for drug discovery and development. Noveris’ dedicated multinational team constantly develops new paths for breakthrough treatment solutions in areas with considerable unmet needs. By collaborating with some of the world's leading specialists, the Company aspires to responsibly speed up the development of breakthrough medications to provide patients with safer and more effective treatment solutions. At the same time, Noveris’ approach focuses on the next generation of psychedelic medicine by creating innovative compounds with unmatched therapeutic potential through its clinical trial efforts with worldclass scientific and regulatory expertise.  

Forward-Looking Statements  

This news release may contain certain “forward-looking statements” and “forward looking information” within the meaning of applicable Canadian and United States securities laws. When used in this news release, the words “intend”, “assume”, “may”, “will”, or “could” and similar words or expressions are intended to identify forward looking statements or information.

Forward-looking statements in this news release include, without limitation, statements regarding the Company's intentions, statements respecting completion of the LIFE Offering, plans and future actions described herein and the terms thereon. Forward-looking statements are based on certain assumptions, including, without limitation, assumptions regarding the Company’s ability to execute its near‑term operational and business objectives following completion of the LIFE Offering. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements.

The Company does not undertake any obligation to update or revise any forward-looking statements or forward-looking information to reflect new information, future events or otherwise, except as required by applicable laws, rules and regulations.

NEITHER THE CSE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “ 1933 Act ”) or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available.

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

Copyright (c) 2026 TheNewswire - All rights reserved.